A detailed history of Jpmorgan Chase & CO transactions in Pulse Biosciences, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 8,180 shares of PLSE stock, worth $119,100. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,180
Previous 9,233 11.4%
Holding current value
$119,100
Previous $80,000 13.75%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$6.69 - $14.54 $7,044 - $15,310
-1,053 Reduced 11.4%
8,180 $91,000
Q1 2024

May 10, 2024

SELL
$7.8 - $11.02 $18,525 - $26,172
-2,375 Reduced 20.46%
9,233 $80,000
Q4 2023

Feb 12, 2024

BUY
$3.85 - $12.84 $4,338 - $14,470
1,127 Added 10.75%
11,608 $142,000
Q3 2023

Nov 14, 2023

SELL
$4.03 - $8.73 $9,680 - $20,969
-2,402 Reduced 18.64%
10,481 $42,000
Q2 2023

Aug 11, 2023

BUY
$3.67 - $8.64 $47,236 - $111,205
12,871 Added 107258.33%
12,883 $92,000
Q2 2022

Aug 11, 2022

SELL
$1.48 - $4.28 $9,657 - $27,927
-6,525 Reduced 99.82%
12 $0
Q1 2022

May 11, 2022

BUY
$4.21 - $14.79 $4,972 - $17,466
1,181 Added 22.05%
6,537 $32,000
Q3 2021

Nov 12, 2021

BUY
$17.25 - $26.63 $92,391 - $142,630
5,356 New
5,356 $116,000

Others Institutions Holding PLSE

About Pulse Biosciences, Inc.


  • Ticker PLSE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 37,125,900
  • Market Cap $541M
  • Description
  • Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using it...
More about PLSE
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.